
Douglas Adkins, MD, discusses future directions of the KEYNOTE-689 trial of pembrolizumab in head and neck cancer following the agent's FDA approval.

Your AI-Trained Oncology Knowledge Connection!

Douglas Adkins, MD, is a professor in the Division of Oncology at Washington University in St. Louis.

Published: June 16th 2025 | Updated: